Comparative Analysis of Long-Term Outcomes of Submacular Hemorrhage in AMD: A Real-Life Study
Ophthalmologica · 2025
DOI: 10.1159/000548392 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Ophthalmologica, 2025. Verfasst von Nicolas Chirpaz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Edouard Herriot University Hospital, Ophthalmology Department, Hospices Civils de Lyon, Lyon, France, nicolas.chirpaz@chu-lyon.fr. Hauptthemen laut MEDLINE: Visual Acuity, Retinal Hemorrhage, Wet Macular Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Introduction
Submacular hemorrhage (SMH) is a severe complication of neovascular age-related macular degeneration (nAMD), often causing profound vision loss. The aim of this study was to assess the long-term outcomes of SMH patients managed with anti-VEGF monotherapy (MT) versus surgical displacement (SD) and to identify prognostic factors for visual acuity.
Methods
This multicenter retrospective study included patients with SMH secondary to nAMD treated in three hospitals in Lyon between 2018 and 2023. Patients were treated with MT or underwent pneumatic displacement (PD) or SD. The best-corrected visual acuity (BCVA) and clinical parameters were assessed at baseline (time of SMH onset), months 1, 3, 9, and 12.
Results
Sixty-six eyes were included: 33 received MT, 6 underwent PD, and 27 underwent SD. The baseline VA was strongly reduced (mean BCVA: 0.14). The VA improved to 0.21 at M1, 0.29 at M3, and 0.33 at M6 but was stabilized at 0.28 at M12. At M12, VA did not significantly differ between MT and SD groups (0.27 vs. 0.32, p = 0.624). However, multivariate analysis revealed a significantly greater VA gain in the SD group (p = 0.025), despite more severe baseline characteristics. SMH thickness was significantly associated with a poorer VA (p = 0.02).
Conclusion
SD may offer greater visual improvement in cases of large and thick SMH. Maximum SMH thickness appears to be a key prognostic factor. Treatment decisions should consider initial hemorrhage severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Edouard Herriot University Hospital, Ophthalmology Department, Hospices Civils de Lyon, Lyon, France, nicolas.chirpaz@chu-lyon.fr.
- Claude Bernard Lyon 1 University, Lyon, France, nicolas.chirpaz@chu-lyon.fr.
- Edouard Herriot University Hospital, Ophthalmology Department, Hospices Civils de Lyon, Lyon, France.
- Croix Rousse University Hospital, Ophthalmology Department, Hospices Civils de Lyon, Lyon, France.
- Laboratoire MATEIS, UMR-CNRS 5510, INSA, Université Lyon 1, Lyon, France.
- Claude Bernard Lyon 1 University, Lyon, France.
Zitieren
APA
Chirpaz, N., Matagrin, B., Gauthier, L., Elbany, S., Rocher, A., Mathis, T., Fenniri, I., Denis, P., Kodjikian, L., Burillon, C., & Dot, C. (2025). Comparative Analysis of Long-Term Outcomes of Submacular Hemorrhage in AMD: A Real-Life Study. Ophthalmologica. https://doi.org/10.1159/000548392
Vancouver
Chirpaz N, Matagrin B, Gauthier L, Elbany S, Rocher A, Mathis T, et al. Comparative Analysis of Long-Term Outcomes of Submacular Hemorrhage in AMD: A Real-Life Study. Ophthalmologica. 2025. doi:10.1159/000548392
BibTeX
@article{Chirpaz2025,
author = {Chirpaz, Nicolas and Matagrin, Benjamin and Gauthier, Lucas and Elbany, Sandra and Rocher, Antonin and Mathis, Thibaud and Fenniri, Inès and Denis, Philippe and Kodjikian, Laurent and Burillon, Carole and Dot, Corinne},
title = {Comparative Analysis of Long-Term Outcomes of Submacular Hemorrhage in AMD: A Real-Life Study},
journal = {Ophthalmologica},
year = {2025},
doi = {10.1159/000548392}
}
EUVIMED